These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 27587460)

  • 1. The lupus impact tracker is responsive to changes in clinical activity measured by the systemic lupus erythematosus responder index.
    Devilliers H; Bonithon-Kopp C; Jolly M
    Lupus; 2017 Apr; 26(4):396-402. PubMed ID: 27587460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lupus Impact Tracker is responsive to physician and patient assessed changes in systemic lupus erythematosus.
    Giangreco D; Devilliers H; Annapureddy N; Block JA; Jolly M
    Lupus; 2015 Dec; 24(14):1486-91. PubMed ID: 26162686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Validation of the Lupus Impact Tracker: A Patient-Completed Tool for Clinical Practice to Evaluate the Impact of Systemic Lupus Erythematosus.
    Jolly M; Kosinski M; Garris CP; Oglesby AK
    Arthritis Rheumatol; 2016 Jun; 68(6):1422-31. PubMed ID: 26814452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-cultural validation of Lupus Impact Tracker in five European clinical practice settings.
    Schneider M; Mosca M; Pego-Reigosa JM; Gunnarsson I; Maurel F; Garofano A; Perna A; Porcasi R; Devilliers H
    Rheumatology (Oxford); 2017 May; 56(5):818-828. PubMed ID: 28204765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials.
    Touma Z; Gladman DD; Ibañez D; Taghavi-Zadeh S; Urowitz MB
    J Rheumatol; 2011 Nov; 38(11):2395-9. PubMed ID: 21885488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life assessed by LupusQoL questionnaire and SF-36 in Turkish patients with systemic lupus erythematosus.
    Yilmaz-Oner S; Oner C; Dogukan FM; Moses TF; Demir K; Tekayev N; Atagunduz P; Tuglular S; Direskeneli H
    Clin Rheumatol; 2016 Mar; 35(3):617-22. PubMed ID: 25846834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months.
    Touma Z; Urowitz MB; Taghavi-Zadeh S; Ibañez D; Gladman DD
    Rheumatology (Oxford); 2012 Oct; 51(10):1814-9. PubMed ID: 22718868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the Lupus Impact Tracker in an Australian patient cohort.
    Antony A; Kandane-Rathnayake RK; Ko T; Boulos D; Hoi AY; Jolly M; Morand EF
    Lupus; 2017 Jan; 26(1):98-105. PubMed ID: 27516435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE.
    Devilliers H; Amoura Z; Besancenot JF; Bonnotte B; Pasquali JL; Wahl D; Maurier F; Kaminsky P; Pennaforte JL; Magy-Bertrand N; Arnaud L; Binquet C; Guillemin F; Bonithon-Kopp C
    Rheumatology (Oxford); 2015 May; 54(5):940-9. PubMed ID: 25361539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
    Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
    Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 Trial.
    Jolly M; Annapureddy N; Arnaud L; Devilliers H
    Lupus; 2019 Dec; 28(14):1628-1639. PubMed ID: 31674267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of systemic lupus erythematosus responder index for detecting clinician-rated responders in patients with active systemic lupus erythematosus.
    Leosuthamas P; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
    Int J Rheum Dis; 2023 Apr; 26(4):667-672. PubMed ID: 36802112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
    Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA;
    Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT.
    Conti F; Perricone C; Reboldi G; Gawlicki M; Bartosiewicz I; Pacucci VA; Massaro L; Miranda F; Truglia S; Alessandri C; Spinelli FR; Teh LS; Ceccarelli F; Valesini G
    Lupus; 2014 Jul; 23(8):743-51. PubMed ID: 24569393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus.
    Mina R; Klein-Gitelman MS; Nelson S; Eberhard BA; Higgins G; Singer NG; Onel K; Tucker L; O'Neil KM; Punaro M; Levy DM; Haines K; Martini A; Ruperto N; Lovell D; Brunner HI
    Ann Rheum Dis; 2014 Feb; 73(2):401-6. PubMed ID: 23345596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.
    Furie R; Petri MA; Strand V; Gladman DD; Zhong ZJ; Freimuth WW;
    Lupus Sci Med; 2014; 1(1):e000031. PubMed ID: 25396065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel evidence-based systemic lupus erythematosus responder index.
    Furie RA; Petri MA; Wallace DJ; Ginzler EM; Merrill JT; Stohl W; Chatham WW; Strand V; Weinstein A; Chevrier MR; Zhong ZJ; Freimuth WW
    Arthritis Rheum; 2009 Sep; 61(9):1143-51. PubMed ID: 19714615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity and reliability of the Lupus QoL index in Turkish systemic lupus erythematosus patients.
    Pamuk ON; Onat AM; Donmez S; Mengüs C; Kisacik B
    Lupus; 2015 Jul; 24(8):816-21. PubMed ID: 25542903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health related quality of life in Mexican women with systemic lupus erythematosus: a descriptive study using SF-36 and LupusQoL(C).
    García-Carrasco M; Mendoza-Pinto C; Cardiel MH; Méndez-Martínez S; García-Villaseñor A; Jiménez-Hernández C; Alonso-García NE; Briones-Rojas R; Ramos-Álvarez G; López-Colombo A
    Lupus; 2012 Oct; 21(11):1219-24. PubMed ID: 22875651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?
    Touma Z; Gladman DD; Ibañez D; Urowitz MB
    J Rheumatol; 2011 Sep; 38(9):1898-905. PubMed ID: 21724700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.